Balyasny Asset Management LLC Cara Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.24 - $12.56 $70,715 - $107,789	8,582 Added 78.69%	19,488 $182,000
Q2 2022 Aug 15, 2022	BUY	$7.45 - $13.84 $81,249 - $150,939	10,906 New	10,906 $100,000
Q2 2020 Aug 14, 2020	SELL	$12.39 - $17.33 $213,702 - $298,907	-17,248 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$9.12 - $17.78 $157,301 - $306,669	17,248 New	17,248 $228,000
Q3 2019 Nov 14, 2019	SELL	$18.28 - $26.91 $222,577 - $327,656	-12,176 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$17.68 - $21.57 $215,271 - $262,636	12,176 New	12,176 $262,000
Q1 2019 May 15, 2019	SELL	$14.41 - $19.64 $217,374 - $296,269	-15,085 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$12.45 - $23.47 $69,881 - $131,737	-5,613 Reduced 27.12%	15,085 $196,000
Q3 2018 Nov 14, 2018	BUY	$17.57 - $23.95 $363,663 - $495,717	20,698 New	20,698 $496,000
Q4 2017 Feb 14, 2018	SELL	$11.86 - $14.08 $1.19 Million - $1.41 Million	-100,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$12.6 - $16.34 $1.26 Million - $1.63 Million	100,000	100,000 $1.37 Million

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.